Biomega invests in a new biorefinery in Denmark
Type of post: NEWS IN BRIEF.
Biomega has announced the expansion of its biorefining assets by investing in a greenfield site in Hirtshals (Denmark). The new biorefinery follows the company’s recent upgrade of its flagship site, strategically located on the west coast of Norway, near Bergen.
Press release: “Biomega Group invests in new biorefinery in Denmark to support growth in Human Health & Nutrition”, 11/05/2021.
Biomega uses its continuous enzymatic hydrolysis process to transform fresh salmon parts into high value, food grade, hydrolysed salmon proteins and oils for the premium food and petfood, health and nutrition sectors. Biomega has four patents for its continuous biorefining process and has invested over 20 years in research and development in sustainable nutrition and biorefining.
The investment is focused on expanding the production capacity and supporting the company’s plans to grow its new salmon peptide business for the human health and nutrition market, which is due for launch in 2021. It will also facilitate continued growth of its Salmigo range designed for premium petfood segments.
AMERRA Capital Management, which acquired Biomega in 2017, invested additional capital for the execution of this project alongside Natixis Investment Managers affiliated asset manager Mirova Natural Capital, and several members of the management team, including the original founders of Biomega.